Partner login Start About us Products News Partners Contact Finance Meet Us Start / About us Board of directors Management Quality assurance Visit us About us Diagnostic Tools for Reliable Patient Management IDL Biotech is a diagnostic company that develops, produces, and markets In Vitro Diagnostic (IVD) tests worldwide for the health care sector. We are active in the fields of oncology and bacteriology through manufacturing of various tumor markers and a rapid Salmonella typhoid test. IDL Biotech AB (publ) is a public company listed on the Swedish equities market place, Aktietorget. IDL's products enable disease diagnosis and prognosis, control of treatment efficiency, and prolong the interval between more invasive patient examinations. We are located just outside Stockholm, Sweden, where all company functions, including management, sales & marketing, orders & shipping, R&D, production, and quality assurance can be found. IDL's products are distributed primarily in Europe and Asia through a network of international business partners. Our history In 1988, IDL was founded under the name IDL Immuno Develop Lab. 10 years later the company name was changed to IDL Biotech AB (publ). IDL Biotech AB (publ) has been listed on the Swedish equities market place, Aktietorget, since 1999. Print Products TPS® MonoTotal® UBC® TPAcyk® TUBEX® TF The Company About us Management News Contact us Partners Legal disclaimer Contact us IDL Biotech AB (publ) PO Box 11151 SE-161 11 Bromma Sweden Phone: +46 8 799 67 50 E-mail: idlbiotech@idl.se

Partner login Start About us Products News Partners Contact Finance Meet Us UBC For Bladder Cancer detection ‹ › Patent approved in China During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. The patent has now been approved in China and is valid until 2034. Read more here Positive results for UBC® Rapid in an Austrian study Read the news here IDL will participate at MEDICA, the world’s largest event for the medical sector. Medica is held 13-16 November, 2017, in Düssseldorf, Germany. You will find us in Hall 3A, booth D28. IDL will also participate in the Swedish Association of Urology in Gothenburg, Sweden October 4-6, 2017. Positive results for UBC® Rapid - UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours in a German multicenter study. Read more here - Positive results for UBC® Rapid in a Swedish multicenter study. Read more here Oncology products Cytokeratin Tumor markers > TPS® > MonoTotal® > TPAcykTM > UBC® Bacteriology products Detection of acute typhoid fever > TUBEX® TF Products TPS® MonoTotal® UBC® TPAcyk® TUBEX® TF The Company About us Management News Contact us Partners Legal disclaimer Contact us IDL Biotech AB (publ) PO Box 11151 SE-161 11 Bromma Sweden Phone: +46 8 799 67 50 E-mail: idlbiotech@idl.se